ReviewFrontiers in immunology2026
Immunological aspects of halo nevus (Sutton's Nevus).
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Halo Nevus as a Self-Limited Model of Melanocyte Autoimmunity: Bridging Vitiligo, Immune Resolution, and Tumor Immunology-A Narrative Review.Dermatopathology (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Halo nevus has historically been observed as a localized skin phenomenon surrounding a melanocytic nevus. However, emerging studies indicate that halo nevus serves as a model for immune-mediated, primarily CD8+ T cells-targeted destruction of melanocytes, similar to vitiligo or regressing melanoma. The aim of this mini-review is to summarize the current understanding of the immunological mechanisms underlying halo nevus formation, to highlight similarities and differences between halo nevus and vitiligo, as well as contrasts with regressing melanoma. Acknowledging halo nevus as a model for a controlled immune response against melanocytes could offer valuable insights into understanding triggers, potential antigens, and the balance of effector and regulatory responses, with translational relevance to pigment disorders and tumor immunology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.